These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32407745)

  • 21. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z; Wei X; Shen L; Zhu H; Zheng X
    Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intranasal delivery of targeted polyfunctional gold-iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide.
    Sukumar UK; Bose RJC; Malhotra M; Babikir HA; Afjei R; Robinson E; Zeng Y; Chang E; Habte F; Sinclair R; Gambhir SS; Massoud TF; Paulmurugan R
    Biomaterials; 2019 Oct; 218():119342. PubMed ID: 31326657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of solvent used for fabrication on drug loading and release kinetics of electrosprayed temozolomide-loaded PLGA microparticles for the treatment of glioblastoma.
    Rodriguez de Anda DA; Ohannesian N; Martirosyan KS; Chew SA
    J Biomed Mater Res B Appl Biomater; 2019 Oct; 107(7):2317-2324. PubMed ID: 30767394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temozolomide for high grade glioma.
    Hart MG; Grant R; Garside R; Rogers G; Somerville M; Stein K
    Cochrane Database Syst Rev; 2008 Oct; (4):CD007415. PubMed ID: 18843749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Targeting of Transcription and Metabolism in Glioblastoma.
    Su YT; Chen R; Wang H; Song H; Zhang Q; Chen LY; Lappin H; Vasconcelos G; Lita A; Maric D; Li A; Celiku O; Zhang W; Meetze K; Estok T; Larion M; Abu-Asab M; Zhuang Z; Yang C; Gilbert MR; Wu J
    Clin Cancer Res; 2018 Mar; 24(5):1124-1137. PubMed ID: 29254993
    [No Abstract]   [Full Text] [Related]  

  • 26. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
    Zhang G; Huang S; Wang Z
    J Clin Neurosci; 2012 Dec; 19(12):1636-40. PubMed ID: 23047061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma.
    Gilbert MR; Pugh SL; Aldape K; Sorensen AG; Mikkelsen T; Penas-Prado M; Bokstein F; Kwok Y; Lee RJ; Mehta M
    J Neurooncol; 2017 Jan; 131(1):193-199. PubMed ID: 27770279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420.
    Lieberman FS; Wang M; Robins HI; Tsien CI; Curran WJ; Werner-Wasik M; Smith RP; Schultz C; Hartford AC; Zhang P; Mehta MP
    Int J Radiat Oncol Biol Phys; 2019 Mar; 103(4):878-886. PubMed ID: 30496882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of submicron/nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice.
    Ranganath SH; Fu Y; Arifin DY; Kee I; Zheng L; Lee HS; Chow PK; Wang CH
    Biomaterials; 2010 Jul; 31(19):5199-207. PubMed ID: 20350766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial.
    Elinzano H; Toms S; Robison J; Mohler A; Carcieri A; Cielo D; Donnelly J; Disano D; Vatketich J; Baekey J; Sturtevant A; MacKinnon K; Wood R; Safran H
    Am J Clin Oncol; 2021 Feb; 44(2):49-52. PubMed ID: 33284237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained Delivery of Doxorubicin via Acetalated Dextran Scaffold Prevents Glioblastoma Recurrence after Surgical Resection.
    Graham-Gurysh E; Moore KM; Satterlee AB; Sheets KT; Lin FC; Bachelder EM; Miller CR; Hingtgen SD; Ainslie KM
    Mol Pharm; 2018 Mar; 15(3):1309-1318. PubMed ID: 29342360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide.
    Cui Y; Naz A; Thompson DH; Irudayaraj J
    Mol Pharm; 2015 Apr; 12(4):1279-88. PubMed ID: 25751281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
    Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
    Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance.
    Yu F; Li G; Gao J; Sun Y; Liu P; Gao H; Li P; Lei T; Chen Y; Cheng Y; Zhai X; Sayari AJ; Huang H; Mu Q
    Cell Prolif; 2016 Apr; 49(2):195-206. PubMed ID: 26923184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
    Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
    J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice.
    Jones-Bolin S; Zhao H; Hunter K; Klein-Szanto A; Ruggeri B
    Mol Cancer Ther; 2006 Jul; 5(7):1744-53. PubMed ID: 16891460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spatiotemporal combination of thermosensitive polypeptide fused interferon and temozolomide for post-surgical glioblastoma immunochemotherapy.
    Liang P; Wang G; Liu X; Wang Z; Wang J; Gao W
    Biomaterials; 2021 Jan; 264():120447. PubMed ID: 33069137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.